Asian Market: Discovering 3 Stocks That May Be Trading Below Their Estimated Value
As the Asian markets navigate through a period of economic recalibration amid global trade uncertainties and evolving inflation dynamics, investors are increasingly focused on identifying opportunities that may be trading below their intrinsic value. In this context, understanding what constitutes an undervalued stock is crucial—typically characterized by strong fundamentals and potential for growth that isn't fully reflected in their current market price.
Name
Current Price
Fair Value (Est)
Discount (Est)
Xiamen Amoytop Biotech (SHSE:688278)
CN¥77.25
CN¥153.79
49.8%
Range Intelligent Computing Technology Group (SZSE:300442)
CN¥42.93
CN¥85.11
49.6%
RACCOON HOLDINGS (TSE:3031)
¥820.00
¥1617.60
49.3%
H.U. Group Holdings (TSE:4544)
¥3049.00
¥6011.28
49.3%
Shenzhen Yinghe Technology (SZSE:300457)
CN¥17.25
CN¥34.44
49.9%
cottaLTD (TSE:3359)
¥432.00
¥853.28
49.4%
Zhuhai CosMX Battery (SHSE:688772)
CN¥13.52
CN¥27.01
49.9%
Heartland Group Holdings (NZSE:HGH)
NZ$0.79
NZ$1.58
49.9%
Dive (TSE:151A)
¥919.00
¥1819.21
49.5%
China Kings Resources GroupLtd (SHSE:603505)
CN¥21.43
CN¥42.38
49.4%
Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Here's a peek at a few of the choices from the screener.
Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products in China, the United States, and internationally, with a market cap of approximately HK$104.09 billion.
Operations: Innovent Biologics generates revenue primarily from its biotechnology segment, amounting to CN¥9.42 billion.
Estimated Discount To Fair Value: 42.1%
Innovent Biologics is trading at HK$63.1, significantly below its estimated fair value of HK$109.06, suggesting it may be undervalued based on cash flows. With earnings expected to grow 41.08% annually and anticipated profitability within three years, the company shows promising financial prospects despite a forecasted low return on equity of 13.9%. Recent advancements in clinical trials for treatments like picankibart and mazdutide could enhance future revenue streams and market positioning in Asia's biopharma sector.
Our earnings growth report unveils the potential for significant increases in Innovent Biologics' future results.
Take a closer look at Innovent Biologics' balance sheet health here in our report.
Overview: Eastroc Beverage(Group) Co., Ltd. focuses on the research, development, production, and sales of beverages in China with a market cap of CN¥166.40 billion.
Operations: The company generates revenue of CN¥17.20 billion from the production, sales, and wholesale of beverages and pre-packaged foods in China.
Estimated Discount To Fair Value: 17.1%
Eastroc Beverage(Group) Co., Ltd. is trading at CNY 320, below its estimated fair value of CNY 386.2, highlighting potential undervaluation based on cash flows. The company reported strong earnings growth with net income reaching CNY 980.01 million in Q1 2025, up from CNY 663.88 million a year ago. Despite an unstable dividend track record, forecasted earnings and revenue growth outpace the Chinese market average, reflecting robust financial health and future prospects.
Our comprehensive growth report raises the possibility that Eastroc Beverage(Group) is poised for substantial financial growth.
Click here and access our complete balance sheet health report to understand the dynamics of Eastroc Beverage(Group).
Overview: Fujikura Ltd. operates in the energy, telecommunications, electronics, automotive, and real estate sectors across Japan, the United States, China, and internationally with a market cap of approximately ¥1.88 trillion.
Operations: Fujikura Ltd.'s revenue is derived from its operations in the energy, telecommunications, electronics, automotive, and real estate sectors across various international markets.
Estimated Discount To Fair Value: 21.3%
Fujikura Ltd. is trading at ¥6,808, significantly below its estimated fair value of ¥8,651.86, suggesting it may be undervalued based on cash flows. The company's earnings grew by 78.6% over the past year and are expected to continue outpacing the Japanese market with a forecasted annual growth of 10%. Despite a volatile share price and an unstable dividend track record, Fujikura's revenue growth prospects remain strong relative to market averages.
In light of our recent growth report, it seems possible that Fujikura's financial performance will exceed current levels.
Click to explore a detailed breakdown of our findings in Fujikura's balance sheet health report.
Click here to access our complete index of 307 Undervalued Asian Stocks Based On Cash Flows.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:1801 SHSE:605499 and TSE:5803.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Via Rail CEO blames plummeting on-time performance on new CN speed rules
MONTREAL - Via Rail says its on-time performance fell drastically in the first three months of the year — a drop the Crown corporation blames largely on new speed rules from Canadian National Railway Co. Via is reporting that its trains, which run mostly on CN tracks, pulled into the station within 15 minutes of their scheduled arrival time only 30 per cent of the time last quarter, down from 72 per cent in the same period the year before. It says ridership decreased by 2.7 per cent, marking the first dip since the railway's pandemic recovery began. Via CEO Mario Péloquin says its ongoing service disruptions are the direct result of 'arbitrary and unnecessary' speed restrictions on new passenger trains that run along its busiest corridors — though heavy snowfall in February was also a likely factor. CN spokeswoman Ashley Michnowski says it is disappointed Via 'refuse(s) to assume responsibility' for its choice to buy trains that could have safety shortcomings, adding that CN has no interest in arbitrarily slowing locomotives on its tracks. Via says its first-quarter operating loss before federal funding and income taxes sagged to $160 million from $151.3 million a year earlier. This report by The Canadian Press was first published June 4, 2025. Companies in this story: (TSX:CNR)
Yahoo
2 hours ago
- Yahoo
Via Rail CEO blames plummeting on-time performance on new CN speed rules
MONTREAL — Via Rail says its on-time performance fell drastically in the first three months of the year — a drop the Crown corporation blames largely on new speed rules from Canadian National Railway Co. Via is reporting that its trains, which run mostly on CN tracks, pulled into the station within 15 minutes of their scheduled arrival time only 30 per cent of the time last quarter, down from 72 per cent in the same period the year before. It says ridership decreased by 2.7 per cent, marking the first dip since the railway's pandemic recovery began. Via CEO Mario Péloquin says its ongoing service disruptions are the direct result of "arbitrary and unnecessary" speed restrictions on new passenger trains that run along its busiest corridors — though heavy snowfall in February was also a likely factor. CN spokeswoman Ashley Michnowski says it is disappointed Via "refuse(s) to assume responsibility" for its choice to buy trains that could have safety shortcomings, adding that CN has no interest in arbitrarily slowing locomotives on its tracks. Via says its first-quarter operating loss before federal funding and income taxes sagged to $160 million from $151.3 million a year earlier. This report by The Canadian Press was first published June 4, 2025. Companies in this story: (TSX:CNR) The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
7 hours ago
- Forbes
China Market Update: Consumer & Health Care Stocks Outperform Despite More Trade Drama
CLN Asian equities were mostly higher overnight as Korea and Taiwan outperformed while the Philippines and Thailand underperformed, as most local currencies gained against the US dollar. Hong Kong gained overnight and was one of the top-performing regional markets amid optimism about a trade deal despite Trump's comments about Xi being 'extremely hard' to deal with. The market also shrugged off the increase in steel tariffs by the US overnight. While the situation appears to be deteriorating, Trump did also heap praise on the Chinese leader, saying he 'always liked him'. The president apparently recognizes Xi as a tough negotiator, just as he presents himself to be. Fingers crossed for a deal soon! Though, they can also always extend the truce and exemptions. After lowering its growth expectations for the US, the OECD also lowered growth expectations for China's economy on trade issues, but left its GDP growth estimate for 2024 unchanged at 4.7%. Remember exports to the US represent only 2% of China's GDP, and they definitely will not even be going to zero! Combined with stimulus, the hit to GDP will be very minimal. Nonetheless, I cannot emphasize enough investors should focus on growth and technology and companies focused on domestic demand! We saw this play out overnight as consumer-oriented names outperformed significantly. Healthcare was a top-performing sector in both Hong Kong and Mainland China. Innovent Biologics gained +14% after the first phase of a trial of its new obesity medication. Meanwhile, nuclear energy company CGN Mining surged +23%, consumer names such as Pop Mart and Miniso were especially strong, and the electric vehicle (EV) ecosystem rebounded as investors finally realized that May sales data were strong. The Ministry of Industry and Information Technology (MIIT) announced new support for the use of electric vehicles, especially in rural areas in Western China. This is a key a market for growth but is plagued by the lack of charging infrastructure. South Korea's decisive election result calmed its markets and represents a return of political stability in the nation after martial law was introduced this past December. South Korea's markets and currency have been volatile, despite companies like SK Hynix being important players in global AI development. New Content Read our latest article: New Drivers For China Healthcare: AI Med-Tech Innovation, Cancer Treatment, & Favorable Balance of Trade Please click here to read Chart1 Chart2 Chart3 Chart4 Chart5 Chart6
